Anzeige
Mehr »
Login
Donnerstag, 01.10.2020 Börsentäglich über 12.000 News von 645 internationalen Medien
Erneut Insiderkäufe! Modern Meat “boomt”: Aktie legt “Rallyegang” ein!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 571050 ISIN: DE0005710503 Ticker-Symbol: N/A 
1-Jahres-Chart
EMPRISE AG Chart 1 Jahr
5-Tage-Chart
EMPRISE AG 5-Tage-Chart

Aktuelle News zur EMPRISE

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18.06.Emprise Capital: Barolo Ventures Announces New Director438VANCOUVER, BC, CANADA / ACCESSWIRE / June 17, 2020 / Barolo Ventures Corp. (TSXV:BVC.H)(the "Company"), announces that Rick Cox has been appointed as a director of the Company, and Scott Ackerman has...
► Artikel lesen
20.05.Emprise Capital: EGF Theramed Health Comments on Recent Market Activity395VANCOUVER, BC / ACCESSWIRE / May 19, 2020 / EGF THERAMED HEALTH CORP. (CSE:TMED)(OTCQB:EVAHF)(FRA:AUHP) (the "Company"). The Company has recently traded higher than normal volumes due to recent marketing...
► Artikel lesen
EMPRISE Aktie jetzt für 0€ handeln
19.03.Emprise Capital: ECC Ventures 2 Announces Amendment to Definitive Agreement to Acquire Long Island Beverages425NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES. VANCOUVER, BC / ACCESSWIRE / March 19, 2020 / ECC Ventures 2 Corp. ("ECC2" or the "Company") (TSXV:ETWO.P)...
► Artikel lesen
18.02.Emprise Capital: NeutriSci Increases Financing To $1.15 Million492VANCOUVER, BC / ACCESSWIRE / February 18, 2020 / NeutriSci International Inc. ("NeutriSci" or the "Company") (TSX-V:NU, OTCQB:NRXCF, FRANKFURT:1N9) the innovator and pioneer behind neuenergy® is pleased...
► Artikel lesen
17.11.19Lilly Announces Interim Analysis From EMPRISE Real-world Study968INDIANAPOLIS (dpa-AFX) - Eli Lilly and Co. (LLY) said that a new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty or EMPRISE real-world study...
► Artikel lesen
17.11.19Interim analysis from EMPRISE real-world study shows empagliflozin decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists785This analysis on effectiveness also shows empagliflozin was associated with a similar risk of non-fatal atherosclerotic cardiovascular events compared with DPP-4 inhibitors or GLP-1 receptor agonists1...
► Artikel lesen
6 Nachrichten in den letzten 12 Monaten